Floatz logo

Eflornithine

Precancerous Condition

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Precancerous Condition cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Cyclophosphamide
Institut Paoli-Calmettes
Phase 2BB
CYCLOSPORIN A
Institut Paoli-Calmettes
Phase 2BB
Fludarabine
Institut Paoli-Calmettes
Phase 2BB

View all 50 →

Same molecule, other indications

Eflornithine is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
66 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →